SOAT1 and myelofibrosis: Other drugs targeting the Jak/Stat pathway that have been developed more recently than the MIPE 4.0 drug library could also be investigated, such as Ruxolitenib—a JAK1/2 inhibitor that is FDA approved for the indication of myelofibrosis and topically for atopic dermatitis.